A new platform for profiling degradation-related impurities via exploiting the opportunities offered by ion-selective electrodes: Determination of both diatrizoate sodium and its cytotoxic degradation product

dc.AffiliationOctober University for modern sciences and Arts (MSA)
dc.contributor.authorRiad S.M.
dc.contributor.authorAbd El-Rahman M.K.
dc.contributor.authorFawaz E.M.
dc.contributor.authorShehata M.A.
dc.contributor.otherCairo University
dc.contributor.otherFaculty of Pharmacy
dc.contributor.otherAnalytical Chemistry Department
dc.contributor.otherKasr-El Aini St
dc.contributor.otherCairo
dc.contributor.other11562
dc.contributor.otherEgypt; October University for Modern Sciences and Arts
dc.contributor.otherFaculty of Pharmacy
dc.contributor.otherAnalytical Chemistry Department
dc.contributor.other6th of October City
dc.contributor.otherEgypt
dc.date.accessioned2020-01-09T20:41:07Z
dc.date.available2020-01-09T20:41:07Z
dc.date.issued2018
dc.descriptionScopus
dc.description.abstractAlthough the ultimate goal of administering active pharmaceutical ingredients (APIs) is to save countless lives, the presence of impurities and/or degradation products in APIs or formulations may cause harmful physiological effects. Today, impurity profiling (i.e., the identity as well as the quantity of impurity in a pharmaceutical) is receiving critical attention from regulatory authorities. Despite the predominant use of spectroscopic and chromatographic methods over electrochemical methods for impurity profiling of APIs, this work investigates the opportunities offered by electroanalytical methods, particularly, ion-selective electrodes (ISEs), for profiling degradation-related impurities (DRIs) compared with conventional spectroscopic and chromatographic methods. For a meaningful comparison, diatrizoate sodium (DTA) was chosen as the anionic X-ray contrast agent based on its susceptibility to deacetylation into its cytotoxic and mutagenic degradation product, 3,5-diamino-2,4,6 triiodobenzoic acid (DTB). This cationic diamino compound can be also detected as an impurity in the final product because it is used as a synthetic precursor for the synthesis of DTA. In this study, four novel sensitive and selective sensors for the determination of both DTA and its cytotoxic degradation products are presented. Sensors I and II were developed for the determination of the anionic drug, DTA, and sensors III and IV were developed for the determination of the cationic cytotoxic impurity. The use of these novel sensors not only provides a stability-indicating method for the selective determination of DTA in the presence of its degradation product, but also permits DRI profiling. Moreover, a great advantage of these proposed ISE systems is their higher sensitivity for the quantification of DTB relative to other spectroscopic and chromatographic methods, so it can measure trace amounts of DTB impurities in DTA bulk powder and pharmaceutical formulation without a need for preliminary separation. � 2018 AOAC International. All rights reserved.en_US
dc.description.urihttps://www.scimagojr.com/journalsearch.php?q=23412&tip=sid&clean=0
dc.identifier.doihttps://doi.org/10.5740/jaoacint.16-0369
dc.identifier.doiPubMed ID 28886756
dc.identifier.issn10603271
dc.identifier.otherhttps://doi.org/10.5740/jaoacint.16-0369
dc.identifier.otherPubMed ID 28886756
dc.identifier.urihttps://t.ly/dOgEM
dc.language.isoEnglishen_US
dc.publisherAOAC Internationalen_US
dc.relation.ispartofseriesJournal of AOAC International
dc.relation.ispartofseries101
dc.subjectOctober University for Modern Sciences and Arts
dc.subjectUniversity for Modern Sciences and Arts
dc.subjectMSA University
dc.subjectجامعة أكتوبر للعلوم الحديثة والآداب
dc.subjectAcetylationen_US
dc.subjectChromatographic analysisen_US
dc.subjectChromatographyen_US
dc.subjectDegradationen_US
dc.subjectDrug productsen_US
dc.subjectPhotodegradationen_US
dc.subjectSodiumen_US
dc.subjectActive pharmaceutical ingredientsen_US
dc.subjectChromatographic methodsen_US
dc.subjectElectroanalytical methoden_US
dc.subjectELectrochemical methodsen_US
dc.subjectPharmaceutical formulationen_US
dc.subjectRegulatory authoritiesen_US
dc.subjectSelective determinationen_US
dc.subjectX-ray contrast agentsen_US
dc.subjectIon selective electrodesen_US
dc.subject3,5-diamino-2,4,6-triiodobenzoateen_US
dc.subjectcontrast mediumen_US
dc.subjectdiatrizoateen_US
dc.subjectmutagenic agenten_US
dc.subjectanalogs and derivativesen_US
dc.subjectdevicesen_US
dc.subjectdrug contaminationen_US
dc.subjectelectrochemical analysisen_US
dc.subjecthigh performance liquid chromatographyen_US
dc.subjection selective electrodeen_US
dc.subjectlimit of detectionen_US
dc.subjectpHen_US
dc.subjectproceduresen_US
dc.subjectultraviolet spectrophotometryen_US
dc.subjectChromatography, High Pressure Liquiden_US
dc.subjectContrast Mediaen_US
dc.subjectDiatrizoateen_US
dc.subjectDrug Contaminationen_US
dc.subjectElectrochemical Techniquesen_US
dc.subjectHydrogen-Ion Concentrationen_US
dc.subjectIon-Selective Electrodesen_US
dc.subjectLimit of Detectionen_US
dc.subjectMutagensen_US
dc.subjectSpectrophotometry, Ultravioleten_US
dc.titleA new platform for profiling degradation-related impurities via exploiting the opportunities offered by ion-selective electrodes: Determination of both diatrizoate sodium and its cytotoxic degradation producten_US
dc.typeArticleen_US
dcterms.isReferencedByShah, R.B., Khan, M.A., The Science and Regulatory Perspectives of Emerging Controlled Release Dosage Forms (2011) Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice, pp. 337-349. , Jone Wiley & Sons, New York, USA; (2004) Guidance for Industry PAT�A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance, , Food and D. Administration DHHS, Rockville, MD; T�nnesen, H.H., (2001) Int. J. Pharm., 225, pp. 1-14; G�r�g, S., (2000) Identification and Determination of Impurities in Drugs, , Elsevier, Amesterdam, Netherlands; Technical Requirements for the Registration of Pharmaceuticals for Human Use, Validation of Analytical Procedures: Definitions and Terminology, Stability Testing of New Drug Substances and Products Q1A (R2) (2003) International Conference on Harmonization, p. 4. , ICH Guideline Geneva, Switzerland, Step; Baertschi, S.W., (2006) Trends Anal. Chem., 25, pp. 758-767; G�r�g, S., (2006) Trends Anal. Chem., 25, pp. 755-757; Abd El-Rahman, M.K., Salem, M.Y., (2015) Sens. Actuators B Chem., 220, pp. 255-262; El-Rahman, M.K.A., Rezk, M.R., Mahmoud, A.M., Elghobashy, M.R., (2015) Sens. Actuators B Chem., 208, pp. 14-21; El-Rahman, M.K.A., Zaazaa, H.E., ElDin, N.B., Moustafa, A.A., (2015) Talanta, 132, pp. 52-58; Peeters, K., De Maesschalck, R., Bohets, H., Vanhoutte, K., Nagels, L., (2008) Eur. J. Pharm. Sci., 34, pp. 243-249; Srivastava, A.K., Gaichore, R.R., (2013) J. AOAC Int., 96, pp. 133-141; Ragab, M.T., El-Rahman, M.K.A., Ramadan, N.K., El-Ragehy, N.A., El-Zeany, B.A., (2015) Talanta, 138, pp. 28-35; Weiss, R., Hsu, B., Wheeler, L., Norman, A., Riley, R.F., (1981) Invest. Radiol., 16, pp. 517-524; El-Rahman, M.K.A., Riad, S.M., Gawad, S.A.A., Fawaz, E.M., Shehata, M.A., (2015) Spectrochim. Acta A Mol. Biomol. Spectrosc., 136, pp. 1167-1174; Umezawa, Y., B�hlmann, P., Umezawa, K., Tohda, K., Amemiya, S., (2000) Pure Appl. Chem., 72, pp. 1851-2082; Bakker, E., B�hlmann, P., Pretsch, E., (1997) Chem. Rev., 97, pp. 3083-3132; B�hlmann, P., Pretsch, E., Bakker, E., (1998) Chem. Rev., 98, pp. 1593-1688; Telting-Diaz, M., Bakker, E., (2001) Anal. Chem., 73, pp. 5582-5589; Sp�th, A., K�nig, B., (2010) Beilstein J. Org. Chem., 6, p. 32; Gutsche, C.D., Stoddart, J., (1998) Calixarenes Revisited: Monographs in Supramolecular Chemistry, p. 6. , Royal Society of Chemistry, Cambridge, United Kingdom; (2011) The United States Pharmacopeia (USP 34), National Formulary (NF 29), , Authority of the United States Pharmacopeial Convention Rockville, MD; Fawaz, E.M., El-Rahman, M.K.A., Riad, S.M., Shehata, M.A., (2017) Biomed. Chromatogr., 31; Bakker, E., (2015) Anal. Chem., 87 (3), pp. 1981-1990; Baertschi, S.W., Alsante, K.M., Reed, R.A., (2011) Pharmaceutical Stress Testing: Predicting Drug Degradation, , CRC Press, Florida, USA
dcterms.sourceScopus

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
avatar_scholar_256.png
Size:
6.31 KB
Format:
Portable Network Graphics
Description:
Loading...
Thumbnail Image
Name:
prof._dr._safaa_riad_1.pdf
Size:
580.35 KB
Format:
Adobe Portable Document Format
Description: